GSK and Targacept end billion-dollar neuro alliance
This article was originally published in Scrip
Executive Summary
Targacept has remained upbeat following the termination of a neuro-focused alliance with GlaxoSmithKline signed in 2007. The agreement had allowed for up to $1.5 billion in milestone payments across five therapeutic areas.